Monoclonal antibodies are considered promising therapeutic alternatives to fight antibiotic-resistant bacteria. Upon binding to their targets, they either act alone (e.g., by neutralizing bacterial toxins) or in concert with the host’s immune system (with complement or phagocytes). Storek et al. have described a unique, directly bactericidal antibody against Escherichia coli.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados